Edition:
India

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

31.70USD
2:29am IST
Change (% chg)

$-0.49 (-1.52%)
Prev Close
$32.19
Open
$31.90
Day's High
$32.74
Day's Low
$31.61
Volume
694,382
Avg. Vol
301,258
52-wk High
$50.43
52-wk Low
$27.35

Latest Key Developments (Source: Significant Developments)

Myriad Genetics - Data From 2 Studies Of Vectra Show Statistically Significantly Predicted Response To Tofacitinib, Tracked Response To Rituximab
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS - DATA FROM 2 STUDIES OF VECTRA SHOW STATISTICALLY SIGNIFICANTLY PREDICTED RESPONSE TO TOFACITINIB, TRACKED RESPONSE TO RITUXIMAB.  Full Article

Myriad Genetics Says May Offer, Resell Up To 3 Mln Shares Common Shares
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS INC MAY OFFER AND RESELL UP TO 3.0 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

Myriad's Bracanalysis CDx Supplementary PMA Accepted By FDA For Review
Monday, 18 Jun 2018 

June 18 (Reuters) - Myriad Genetics Inc ::MYRIAD’S BRACANALYSIS CDX® SUPPLEMENTARY PMA ACCEPTED BY FDA FOR REVIEW AS A COMPANION DIAGNOSTIC FOR TALAZOPARIB IN METASTATIC BREAST CANCER.MYRIAD GENETICS - NDA FOR TALAZOPARIB GRANTED PRIORITY REVIEW BY U.S. FDA & HAS PRESCRIPTION DRUG USER FEE ACT GOAL DATE OF DEC 2018.  Full Article

Myriad Genetics Signs Definitive Agreement To Acquire Counsyl
Tuesday, 29 May 2018 

May 28 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS SIGNS DEFINITIVE AGREEMENT TO ACQUIRE COUNSYL, INC..MYRIAD GENETICS INC - DEAL FOR $375 MILLION THROUGH A COMBINATION OF CASH AND MYRIAD COMMON STOCK.MYRIAD GENETICS INC - ON COMPLETION OF TRANSACTION, COUNSYL WILL BECOME A WHOLLY OWNED SUBSIDIARY OF MYRIAD.MYRIAD GENETICS - MYRIAD INTENDS TO FUND TRANSACTION THROUGH CASH ON HAND, AN EXISTING REVOLVING CREDIT FACILITY AND ISSUANCE OF COMMON STOCK.MYRIAD GENETICS-TRANSACTION VALUED AT $375 MILLION IN CASH WITH SHAREHOLDERS HAVING RIGHT TO RECEIVE UP TO 25 PERCENT OF CONSIDERATION IN MYRIAD COMMON STOCK.MYRIAD GENETICS INC - NUMBER OF SHARES DELIVERED TO FORMER COUNSYL SHAREHOLDERS WILL NOT EXCEED 3 MILLION SHARES.  Full Article

Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS ANNOUNCES EXPANDED RESEARCH COLLABORATION WITH ASTRAZENECA.MYRIAD GENETICS INC - FINANCIAL TERMS WERE NOT DISCLOSED..MYRIAD GENETICS INC - UNDER AGREEMENT, MYRIAD WILL USE ITS MYCHOICE HRD PLUS TEST TO EVALUATE PATIENTS ENROLLED IN AN ONGOING PHASE III TRIAL.  Full Article

Myriad Genetics posts Q1 adjusted earnings per share $0.26
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Myriad Genetics Inc :Myriad Genetics reports fiscal first-quarter 2018 financial results.Q1 adjusted earnings per share $0.26.Q1 GAAP earnings per share $1.15.Q1 revenue $190.2 million versus I/B/E/S view $183.4 million.Q1 earnings per share view $0.21 -- Thomson Reuters I/B/E/S.Myriad Genetics Inc sees ‍fiscal year 2018 revenue $750 million to $770 million​.Myriad Genetics Inc sees ‍fiscal year 2018 earnings per share $1.41-$1.46​.Myriad Genetics Inc sees ‍fiscal year 2018 adjusted earnings per share $1.00-$1.05​.Myriad Genetics Inc sees ‍fiscal second-quarter 2018 revenue $187 million to $189 million​.Myriad Genetics Inc sees ‍fiscal second-quarter 2018 earnings per share $0.08-$0.10; sees fiscal second-quarter 2018 adjusted earnings per share $0.22-$0.24​.FY2018 earnings per share view $1.03, revenue view $764.6 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.25, revenue view $189.9 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad submits BRACAnalysis® CDx application for regulatory approval in Japan
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Myriad Genetics Inc :Myriad submits BRACAnalysis® CDX application for regulatory approval in Japan for HER2- metastatic breast cancer.Myriad Genetics Inc - submitted BRACAnalysis CDX in Japan for review by PMDA and marketing approval by Ministry Of Health, Labor and Welfare​.Myriad Genetics Inc - ‍submitted marketing approval as a companion diagnostic to olaparib for use in HER2- metastatic breast cancer patients​.  Full Article

Myriad Genetics’s supplementary PMA for BRACAnalysis CDx accepted by FDA for review
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Myriad Genetics Inc :Myriad’s BRACAnalysis CDx supplementary pma accepted by fda for review as a companion diagnostic for Lynparza (olaparib) in metastatic breast cancer.Myriad Genetics Inc - ‍Myriad expects FDA'S priority review process to conclude in fiscal third-quarter 2018​.  Full Article